264 related articles for article (PubMed ID: 19389237)
1. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis.
Badot V; Galant C; Nzeusseu Toukap A; Theate I; Maudoux AL; Van den Eynde BJ; Durez P; Houssiau FA; Lauwerys BR
Arthritis Res Ther; 2009; 11(2):R57. PubMed ID: 19389237
[TBL] [Abstract][Full Text] [Related]
2. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.
Ducreux J; Durez P; Galant C; Nzeusseu Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
Arthritis Rheumatol; 2014 Jan; 66(1):15-23. PubMed ID: 24449571
[TBL] [Abstract][Full Text] [Related]
3. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.
Dennis G; Holweg CT; Kummerfeld SK; Choy DF; Setiadi AF; Hackney JA; Haverty PM; Gilbert H; Lin WY; Diehl L; Fischer S; Song A; Musselman D; Klearman M; Gabay C; Kavanaugh A; Endres J; Fox DA; Martin F; Townsend MJ
Arthritis Res Ther; 2014; 16(2):R90. PubMed ID: 25167216
[TBL] [Abstract][Full Text] [Related]
4. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients.
Lindberg J; af Klint E; Catrina AI; Nilsson P; Klareskog L; Ulfgren AK; Lundeberg J
Arthritis Res Ther; 2006; 8(6):R179. PubMed ID: 17134501
[TBL] [Abstract][Full Text] [Related]
5. Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines.
Badot V; Durez P; Van den Eynde BJ; Nzeusseu-Toukap A; Houssiau FA; Lauwerys BR
J Cell Mol Med; 2011 Nov; 15(11):2335-42. PubMed ID: 21129157
[TBL] [Abstract][Full Text] [Related]
6. Higher expression of TNFα-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy.
De Groof A; Ducreux J; Humby F; Nzeusseu Toukap A; Badot V; Pitzalis C; Houssiau FA; Durez P; Lauwerys BR
Arthritis Res Ther; 2016 Jan; 18():19. PubMed ID: 26792343
[TBL] [Abstract][Full Text] [Related]
7. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.
Mavragani CP; La DT; Stohl W; Crow MK
Arthritis Rheum; 2010 Feb; 62(2):392-401. PubMed ID: 20112385
[TBL] [Abstract][Full Text] [Related]
8. Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study.
Sundberg E; Grundtman C; Af Klint E; Lindberg J; Ernestam S; Ulfgren AK; Harris HE; Andersson U
Arthritis Res Ther; 2008; 10(2):R33. PubMed ID: 18346273
[TBL] [Abstract][Full Text] [Related]
9. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.
Wijbrandts CA; Dijkgraaf MG; Kraan MC; Vinkenoog M; Smeets TJ; Dinant H; Vos K; Lems WF; Wolbink GJ; Sijpkens D; Dijkmans BA; Tak PP
Ann Rheum Dis; 2008 Aug; 67(8):1139-44. PubMed ID: 18055470
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
11. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
12. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis.
Lindberg J; Wijbrandts CA; van Baarsen LG; Nader G; Klareskog L; Catrina A; Thurlings R; Vervoordeldonk M; Lundeberg J; Tak PP
PLoS One; 2010 Jun; 5(6):e11310. PubMed ID: 20593016
[TBL] [Abstract][Full Text] [Related]
13. Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.
Oswald M; Curran ME; Lamberth SL; Townsend RM; Hamilton JD; Chernoff DN; Carulli J; Townsend MJ; Weinblatt ME; Kern M; Pond CM; Lee A; Gregersen PK
Arthritis Rheumatol; 2015 Feb; 67(2):344-51. PubMed ID: 25371395
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
15. Decrease of CD68 and MMP-3 expression in synovium by treatment of adalimumab for rheumatoid arthritis.
Kanbe K; Chiba J; Nakamura A
Int J Rheum Dis; 2011 Aug; 14(3):261-6. PubMed ID: 21816022
[TBL] [Abstract][Full Text] [Related]
16. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Tsurumoto T; Kono M; Shindo H; Ida H; Origuchi T; Eguchi K
J Rheumatol; 2009 Nov; 36(11):2397-402. PubMed ID: 19797510
[TBL] [Abstract][Full Text] [Related]
17. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor.
Ernestam S; af Klint E; Catrina AI; Sundberg E; Engström M; Klareskog L; Ulfgren AK
Arthritis Res Ther; 2006; 8(1):R18. PubMed ID: 16507118
[TBL] [Abstract][Full Text] [Related]
18. IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis.
Navrátilová A; Andrés Cerezo L; Hulejová H; Bečvář V; Tomčík M; Komarc M; Veigl D; Tegzová D; Závada J; Olejárová M; Pavelka K; Vencovský J; Šenolt L
Front Immunol; 2021; 12():745523. PubMed ID: 34745117
[TBL] [Abstract][Full Text] [Related]
19. Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue.
Triaille C; Durez P; Sokolova T; Tilman G; Méric de Bellefon L; Galant C; Coulie P; Lauwerys BR; Limaye N
Front Immunol; 2021; 12():724895. PubMed ID: 34526997
[TBL] [Abstract][Full Text] [Related]
20. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy.
Chen DY; Chen YM; Chen HH; Hsieh CW; Lin CC; Lan JL
Arthritis Res Ther; 2011 Jul; 13(4):R126. PubMed ID: 21801431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
